• Concerted In Vivo Screening Reveals TSA's Potential in PDA T

  2026-06-16

  This study pioneers a combined cell and in vivo screen to identify effective chemotherapeutic strategies for pancreatic ductal adenocarcinoma (PDA), highlighting the use of Trichostatin A (TSA) as a histone deacetylase inhibitor that both stimulates disease-relevant biomarkers and enhances the efficacy of established drugs. The findings suggest a rational framework for preclinical drug validation and underscore the growing importance of epigenetic modulation in cancer therapy.

• 1-methyl Adenosine in RNA Modification: Applied Protocols &

  2026-06-16

  1-methyl Adenosine (1-methyl Ado) is revolutionizing RNA modification research, empowering robust quantification and advanced biomarker discovery in cancer metabolism studies. Explore optimized workflows and troubleshooting strategies to maximize assay fidelity and translational relevance.

• Targeting AR and ARv7 in TNBC: EPI-001 Modulates Metastasis

  2026-06-15

  This study provides the first detailed analysis of androgen receptor (AR) and its splice variant ARv7 as prognostic biomarkers in triple-negative breast cancer (TNBC). It demonstrates that EPI-001, an androgen receptor N-terminal domain inhibitor, effectively suppresses metastatic and epithelial-to-mesenchymal transition (EMT) pathways in AR/ARv7-positive TNBC models, highlighting a potential strategy for overcoming poor prognosis linked to these markers.

• SGC-CBP30: Targeting Super-Enhancer Hijacking in LUAD

  2026-06-15

  Discover how SGC-CBP30, a potent CREBBP/EP300 bromodomain inhibitor, empowers translational researchers to interrogate super-enhancer hijacking and transcriptional coactivator dynamics in early-stage lung adenocarcinoma (LUAD). This thought-leadership article synthesizes mechanistic insights, experimental approaches, and strategic perspectives—anchored in recent landmark studies—to guide the next wave of epigenetics-driven cancer biology research.

• 3-Deazaneplanocin (DZNep): Precision Epigenetic Modulation i

  2026-06-14

  Explore how 3-Deazaneplanocin (DZNep) enables highly specific epigenetic modulation for advanced oncology research. Discover its unique mechanism, protocol insights, and practical assay strategies that distinguish it from conventional methods.

• Improving In Vitro Drug Response Assessment in Cancer Resear

  2026-06-13

  Schwartz's dissertation introduces a nuanced approach to in vitro anticancer drug evaluation by disentangling proliferative arrest from cell death through dual viability metrics. This distinction enhances experimental rigor and interpretation, enabling more precise assessment of epigenetic modulators like DNA methyltransferase inhibitors in preclinical settings.

• LG 101506: Decoding RXR Modulation for Cancer Immunity Resea

  2026-06-12

  Explore the advanced role of LG 101506 as an RXR modulator in unraveling nuclear receptor signaling and immunological checkpoints in cancer biology. This article delivers deep mechanistic insights and practical assay guidance for researchers investigating RXR pathways and immune evasion.

• 3-Deazaneplanocin (DZNep): Deep-Dive into Epigenetic Modulat

  2026-06-12

  Explore the science and application of 3-Deazaneplanocin (DZNep) as a potent epigenetic modulator, with fresh insights into its dual mechanism, advanced assay protocols, and relevance for cancer stem cell targeting. This article offers a distinct, in-depth analysis bridging molecular innovation to practical oncology workflows.

• Trichostatin A (TSA): Protocols and Advances in Epigenetic C

  2026-06-11

  Trichostatin A (TSA) stands at the forefront of epigenetic research, enabling precise modulation of histone acetylation for mechanistic and translational oncology studies. This guide delivers hands-on protocol tips, advanced troubleshooting, and strategic insight for deploying TSA in workflows that demand both rigor and reproducibility.

• N6-Methyl-dATP (B8093): Reliable Epigenetic Probe for Cell A

  2026-06-11

  This article provides a scenario-driven, evidence-based guide for biomedical researchers and laboratory scientists using N6-Methyl-dATP (SKU B8093). It addresses practical workflow challenges in DNA replication fidelity and epigenetic modification studies, highlighting how APExBIO’s high-purity solution enhances reproducibility and interpretability in cell viability and proliferation assays.

• CHIR-99021 (CT99021): Optimizing Stem Cell Differentiation W

  2026-06-10

  CHIR-99021 (CT99021) stands out as a selective GSK-3 inhibitor that transforms stem cell protocol reliability, particularly in directed differentiation and pluripotency maintenance. Discover how this compound empowers advanced applications—including corneal endothelial cell generation—and master troubleshooting with actionable, evidence-based protocol enhancements.

• Ganetespib (STA-9090): Elevating Hsp90 Inhibition in Cancer

  2026-06-10

  Ganetespib (STA-9090) offers unmatched potency and versatility for targeted Hsp90 inhibition in cancer research, outperforming traditional geldanamycin derivatives. Its unique triazolone scaffold enables robust tumor growth inhibition across diverse cellular and animal models, making it a preferred tool for advanced assay design and translational workflows.

• N6-Methyl-dATP: Shaping Epigenetic Frontiers in Translationa

  2026-06-09

  This article explores the transformative role of N6-Methyl-dATP in advancing epigenetic research, with a focus on acute myeloid leukemia (AML) biology, DNA replication fidelity, and translational applications. Blending mechanistic insight with strategic guidance, it positions APExBIO’s N6-Methyl-dATP as a pivotal tool for researchers seeking to bridge molecular understanding and clinical innovation.

• Procainamide Hydrochloride: Precision Tools for Cardiac and

  2026-06-09

  Explore how Procainamide Hydrochloride enables rigorous cardiac sodium channel blocker studies and high-fidelity epigenetic assays. This article provides advanced protocol strategies, evidence-based insights, and practical recommendations for research beyond standard applications.

• EGCG: Mechanistic Leverage for Translational Antioxidant Res

  2026-06-08

  (-)-Epigallocatechin gallate (EGCG), a green tea-derived polyphenol, has emerged as a pivotal compound at the intersection of cancer chemoprevention, antiangiogenic, and antiviral research. This article unpacks its molecular mechanisms, practical workflow considerations, and the strategic edge it offers translational researchers—anchored by recent neurodegeneration evidence and critical comparisons to traditional antioxidants.

11530 records 1/769 page Next 12345 下5页 Last page